Dr. Kirk Beebe, Director of Application Science, Metabolon, Inc.
In the previous editions of this six-part series, we've explored numerous examples of how metabolomics is bringing success to areas such as cancer, metabolic disease, cardiovascular, and rare-disease research.
By Paul Held, Ph.D., and Peter Banks, Ph.D., BioTek Instruments, Inc.
The imaging and analysis of fluorescently stained cells has traditionally been accomplished using manual microscopic methods with low numbers of samples, while the analysis of higher sample numbers requires the use of very expensive dedicated microscopes.
By Claudia M. Huether-Franken, Anne Niehus, and Sebastian Kleebank
Single-use bioreactor solutions have been successfully established in animal and human cell culture in the past years. Now this technology is going to make its way to microbial applications.
By Mark C. Arjona, Catherine Nguyen, Jenny Y. Bang, Tom Fletcher, and Jessie H.T. Ni
In the production of biologics, various development activities require different medium requirements, calling for multiple media.
By Carrie MacGillivray, AT&T
This white paper examines the high-level industry trends and business requirements for high-value asset tracking and the benefits that M2M can bring to the broader transportation segment. It discusses the opportunities and challenges that these trends present for enterprises looking to invest in a solution that provides connectivity and tracking capability. In addition, the white paper showcases some of the AT&T solutions that help enterprises achieve business performance improvement and operational gains derived from asset tracking and monitoring applications.